RecruitingInterventionalPhase 2Last updated Aug 10, 2026

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

Overview

ClinicalTrials.gov ID: NCT07755410
Lead Sponsor: Alkermes, Inc.INDUSTRY
Brief Summary: The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Aug 2026Estimated
Primary Completion Date: Jul 2027Estimated
Completion Date: Jul 2027Estimated

Study Record Dates

First Submitted: Aug 5, 2026
First Submitted that Met QC Criteria: Aug 5, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 5, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT01692782Completed

Adult Attention Deficit Hyperactivity Disorder

NCT02253745Completed

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

NCT01493726Completed

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT00640185Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697Completed

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03375021Completed

CX717 in the Treatment of Adult ADHD